While DDR1 inhibitors primarily block its kinase activity, DDR1 degraders reduce the total protein levels of DDR1, thereby addressing its roles in both signaling and structural processes that contribute to tumor progression and immune evasion. The gene discussed is DDR1; the disease is neoplasm.